Shari Pilon‐Thomas

5.9k total citations · 2 hit papers
116 papers, 3.9k citations indexed

About

Shari Pilon‐Thomas is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Shari Pilon‐Thomas has authored 116 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Immunology, 76 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Shari Pilon‐Thomas's work include Immunotherapy and Immune Responses (62 papers), CAR-T cell therapy research (44 papers) and Cancer Immunotherapy and Biomarkers (41 papers). Shari Pilon‐Thomas is often cited by papers focused on Immunotherapy and Immune Responses (62 papers), CAR-T cell therapy research (44 papers) and Cancer Immunotherapy and Biomarkers (41 papers). Shari Pilon‐Thomas collaborates with scholars based in United States, Italy and Germany. Shari Pilon‐Thomas's co-authors include James J. Mulé, Amod A. Sarnaik, Krithika N. Kodumudi, Amy Weber, Robert J. Gillies, Arig Ibrahim‐Hashim, H. David Kay, Richard Jove, Tianhong Wang and Wei Sheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Shari Pilon‐Thomas

108 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

2005 813 citations Shari Pilon‐Thomas, James J. Mulé et al. profile →
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy

2016 468 citations Shari Pilon‐Thomas, Krithika N. Kodumudi et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shari Pilon‐Thomas United States	31	2.3k	2.2k	1.1k	590	292	116	3.9k
Andrea Schietinger United States	25	3.5k 1.5×	3.1k 1.4×	1.2k 1.1×	336 0.6×	275 0.9×	41	5.1k
Viviana Cremasco United States	22	1.4k 0.6×	1.6k 0.7×	1.2k 1.0×	469 0.8×	418 1.4×	31	3.3k
Lana E. Kandalaft Switzerland	36	2.5k 1.1×	2.2k 1.0×	1.3k 1.1×	254 0.4×	396 1.4×	93	3.8k
Begonya Comin-Anduix United States	28	2.1k 0.9×	2.6k 1.2×	1.7k 1.5×	338 0.6×	405 1.4×	42	4.3k
Martin W. LaFleur United States	16	2.1k 0.9×	2.0k 0.9×	1.9k 1.6×	424 0.7×	175 0.6×	23	3.9k
Ashley V. Menk United States	24	2.8k 1.2×	1.9k 0.9×	1.5k 1.3×	1.3k 2.1×	335 1.1×	34	4.6k
Paul J. Neeson Australia	33	1.9k 0.8×	2.4k 1.1×	1.4k 1.2×	274 0.5×	467 1.6×	144	4.2k
James N. Arnold United Kingdom	24	2.0k 0.8×	1.4k 0.6×	2.5k 2.2×	399 0.7×	249 0.9×	44	4.5k
Tobias Schatton United States	27	1.4k 0.6×	3.1k 1.4×	2.2k 1.9×	855 1.4×	308 1.1×	40	4.4k
Matthew M. Gubin United States	17	2.8k 1.2×	2.7k 1.2×	1.7k 1.5×	1.2k 2.1×	298 1.0×	22	5.1k

Countries citing papers authored by Shari Pilon‐Thomas

Since Specialization

Citations

This map shows the geographic impact of Shari Pilon‐Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shari Pilon‐Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shari Pilon‐Thomas more than expected).

Fields of papers citing papers by Shari Pilon‐Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shari Pilon‐Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shari Pilon‐Thomas. The network helps show where Shari Pilon‐Thomas may publish in the future.

Co-authorship network of co-authors of Shari Pilon‐Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Shari Pilon‐Thomas. A scholar is included among the top collaborators of Shari Pilon‐Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shari Pilon‐Thomas. Shari Pilon‐Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tordesillas, Leticia, Matthew Beatty, Dongliang Du, et al.. (2025). CD40L stimulates tumor-infiltrating B-cells and improves ex vivo TIL expansion. Journal for ImmunoTherapy of Cancer. 13(4). e011066–e011066. 4 indexed citations

Ramamoorthi, Ganesan, Marie Catherine Lee, Carly M. Farrell, et al.. (2025). Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells. Cancer Immunology Research. 13(5). 729–748. 1 indexed citations

Chahoud, Jad, Marine Potez, Michael Carter, et al.. (2025). Optimizing clear cell renal cell carcinoma tumor-infiltrating lymphocytes under controlled hypoxic conditions.. Journal of Clinical Oncology. 43(5_suppl). 581–581.

Potez, Marine, et al.. (2025). The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers. Nature Reviews Urology. 23(3). 196–212.

Jardim‐Perassi, Bruna V., Dominique Abrahams, Verónica Estrella, et al.. (2024). L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy. Biomedicines. 12(2). 461–461. 6 indexed citations

Markowitz, Joseph, Michael J. Shamblott, Andrew S. Brohl, et al.. (2024). First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0. Molecular Cancer Therapeutics. 23(8). 1139–1143. 5 indexed citations

Fernandez, Mario R., Chunying Yang, Lancia Darville, et al.. (2023). Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 8(18). 15 indexed citations

Giuliano, Anna R., Barbara J. Kuter, Shari Pilon‐Thomas, et al.. (2023). Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients. Cancer Communications. 43(7). 749–764. 6 indexed citations

Beatty, Matthew, MacLean Hall, Larissa A. Pikor, et al.. (2023). 346 Expansion and identification of neoantigen reactive tumor infiltrating lymphocytes (TIL) from metastatic colorectal (CRC) and GI cancers. SHILAP Revista de lepidopterología. A395–A395.

10.

Jardim‐Perassi, Bruna V., Justin Y. C. Lau, Mikalai M. Budzevich, et al.. (2023). Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI. Contrast Media & Molecular Imaging. 2023. 1–12. 7 indexed citations

11.

Zahid, Mohammad U., Jennifer M. Binning, Bryan Q. Spring, et al.. (2022). Rethinking the immunotherapy numbers game. Journal for ImmunoTherapy of Cancer. 10(7). e005107–e005107. 12 indexed citations

12.

Aydın, Ahmet Murat, Patrick Innamarato, Ali Hajiran, et al.. (2020). Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. Journal for ImmunoTherapy of Cancer. 8(2). e001673–e001673. 7 indexed citations

13.

Atay, Çiğdem, Taekyoung Kwak, Sergio Lavilla-Alonso, et al.. (2019). BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Clinical Cancer Research. 25(9). 2783–2794. 26 indexed citations

14.

Falahat, Rana, Patricio Perez-Villarroel, Adam W. Mailloux, et al.. (2019). STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. Cancer Immunology Research. 7(11). 1837–1848. 67 indexed citations

15.

Poleszczuk, Jan, Shari Pilon‐Thomas, Sungjune Kim, et al.. (2018). Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Scientific Reports. 8(1). 9474–9474. 33 indexed citations

16.

Liu, Hao, Amy Weber, Krithika N. Kodumudi, et al.. (2018). T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. PLoS ONE. 13(4). e0196033–e0196033. 16 indexed citations

17.

Schoenfeld, Jonathan D., et al.. (2017). Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy. PubMed. 3(3). 34001–34001. 6 indexed citations

18.

Pilon‐Thomas, Shari, Krithika N. Kodumudi, Asmaa El-Kenawi, et al.. (2016). Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Research. 76(6). 1381–1390. 468 indexed citations breakdown →

19.

Chacon, Jessica, Amod A. Sarnaik, Jie Qing Chen, et al.. (2014). Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. Clinical Cancer Research. 21(3). 611–621. 48 indexed citations

20.

Pilon‐Thomas, Shari, et al.. (2010). Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma. The Journal of Immunology. 184(7). 3442–3449. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact